Format

Send to

Choose Destination
Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Collaborators (459)

Goldhirsch A, Coates AS, Aebi S, Coates AS, Colleoni M, Collins JP, Cortés Funes H, Gelber RD, Goldhirsch A, Green M, Hiltbrunner A, Holmberg SB, Karlsson P, Kössler I, Láng I, Lindtner J, Paganetti F, de Stoppani M, Rudenstam CM, Senn HJ, Stahel R, Thürlimann B, Veronesi A, Hiltbrunner A, Egli G, Rabaglio M, Maibach R, Studer R, Ruepp B, Bärtschi D, Schärlig-Strausak M, Castiglione M, Pagani O, Simoncini E, Gelber R, Price K, Cole B, Gelber S, Regan M, Sun Z, Giobbie-Hurder A, Nickerson L, Blacher L, Hinkle R, Celano J, Scolese T, Gusterson B, Viale G, Mallon E, Veronesi A, Crivellari D, Monfardini S, Galligioni E, Magri MD, Buonadonna A, Massarut S, Rossi C, Candiani E, Carbone A, Volpe R, Roncadin M, Arcicasa M, Coran F, Morassut S, Simoncini E, Marini G, Marpicati P, Lucini L, Grigolato P, Morassi L, Farfaglia R, Bianchi AM, Foladore S, Foghin L, Pamich G, Bianchi C, Marino B, Murgia A, Milan V, Murray E, Dent DM, Gudgeon A, Murray E, Werner ID, Hacking A, Tiltman A, McEvoy E, Toop J, Vorobiof D, Chasen M, Mohammed GC, Schindler AE, Faber P, Schnürch HG, Bender H, Bojar H, Rudenstam CM, Holmberg SB, Karlsson P, Wallgren A, Ottosson-Lönn S, Hultborn R, Colldahl-Jädeström G, Cahlin E, Mattsson J, Ruusvik O, Niklasson LG, Dahlin S, Karlsson G, Lindberg B, Sundbäck A, Bergegârdh S, Groot O, Dahlbäck LO, Salander H, Andersson C, Heideman M, Nissborg A, Wallin A, Claes G, Ramhult T, Svensson JH, Liedberg P, Nilsson A, Oestberg G, Persson S, Matusik J, Goldhirsch A, Colleoni M, Peruzotti G, Viale G, Renne G, Mazzarol G, Martinelli G, Orlando L, Nolè F, Torrisi R, Dellapasqua S, Curigliano G, De Pas T, de Braud F, Cinieri S, Peccatori F, Luini A, Orecchia R, Costa A, Zurrida S, Veronesi P, Sacchini V, Galimberti V, Intra M, Veronesi U, Antimi M, Minelli M, Bellini V, Porzio R, Pernazza E, Santeusanio G, Spagnoli LG, Lindtner J, Erzen D, Cufer T, Majdic E, Stabuc B, Golouh R, Lamovec J, Jancar J, Vrhovec I, Kramberger M, Novak J, Naglas M, Sencar M, Cervek J, Sebek S, Cerar O, Plesnicar A, Zakotnik B, Cortès-Funes H, Mendiola C, Gravalos C, Colomer, Mendez M, Cruz Vigo F, Miranda P, Sierra A, Martinez-Tello F, Garzon A, Alonso S, Ferrero A, Vargas C, Forbes JF, Lindsay D, Simes RJ, Beller E, Stone C, Gebski V, Collins J, Snyder R, Abdi E, Basser R, Bennett R, Briggs P, Brodie P, Burns WI, Chipman M, Chirgwin J, Drummond R, Ellims P, Finkelde D, Francis P, Funder J, Gale T, Green M, Gregory P, Griffiths J, Goss G, Harrison L, Hart S, Henderson M, Humenuik V, Jeal P, Kitchen P, Lindeman G, Mann B, McKendrick J, McLennan R, Millar R, Murphy C, Neil S, Olver I, Pitcher M, Read A, Reading D, Reed R, Richardson G, Rodger A, Russell I, Schwarz M, Sisely L, Stanley R, Steele M, Stewart J, Underhill C, Zalcberg J, Zimet A, Birrell S, Eaton M, Hoffmann C, Koczwara B, Karapetis C, Malden T, McLeay W, Seshadri R, Forbes JF, Stewart J, Jackson D, Gourlay R, Bishop J, Cox S, Ackland S, Bonaventura A, Hamilton C, Denham J, O'Brien P, Back M, Brae S, Price A, Muragasu R, Foster H, Clarke D, Sillar R, MacDonald I, Hitchins R, Olver N, Keefe D, Brown M, Gill PG, Taylor A, Robertson A, Gill PG, Carter ML, Malycha P, Yeoh E, Ward G, Leong AS, Lommax-Smith J, Horsfall D, D'Angelo R, Abdi E, Cleary J, Parnis F, Bayliss E, Byrne M, van Hazel G, Dewar J, Buck M, Ingram D, Sterrett G, Reynolds PM, Sheiner HJ, Shilkin KB, Hahnel R, Levitt S, Kermode D, Hahnel H, Hastrich D, Joseph D, Cameron F, Tattersall HN, Coates A, Niesche F, West R, Renwick S, Donovan J, Duval P, Simes RJ, Ng A, Glenn D, North RA, Beith J, O'Connor RG, Rice M, Stevens G, Grassby J, Pendlebury S, McLeod C, Boyer M, Sullivan A, Hobbs J, Fox R, Hedley D, Raghavan D, Green D, Foo T, Nash TJ, Grygiel J, Lind D, Lewis C, Friedlander M, Kay G, Holdaway IM, Harvey VJ, Benjamin CS, Thompson P, Bierre A, Miller M, Hochstein B, Lethaby A, Webber J, Jagusch MF, Neave L, Mason BM, Evans B, Carter JF, Gillman JC, Mack D, Benson-Cooper D, Probert J, Wood H, Anderson J, Yee L, Hitchcock GC, Lethaby A, Webber J, Porter D, Kennedy I, Round G, Long J, Fey MF, Aebi S, Castiglione-Gertsch M, Dreher E, Buser K, Ludin J, Beck G, Lüthi JM, Altermatt HJ, Nandedkar M, Senn HJ, Thürlimann B, Oehlschlegel Ch, Ries G, Töpfer M, Lorenz U, Ehrsam A, Späti B, Vogel E, Cavalli F, Pagani O, Neuenschwander H, Sessa C, Ghielmini M, Zucca E, Bernier J, Pedrinis ES, Rusca T, Passega E, Bronz L, Rey P, Galfetti M, Sanzeni W, Gyr T, Leidi L, Pastorelli G, Varini M, Longhi S, Cafaro-Greco C, Graffeo R, Goldhirsch A, Herrmann R, Rochlitz CF, Harder JF, Köchli O, Eppenberger U, Torhorst J, Piguet D, Siegenthaler P, Barrelet V, Baumann RP, Pestalozzi B, Sauter C, Haller U, Metzger U, Huguenin P, Caduff R, Perey L, Zaman K, Leyvraz S, De Grandi P, Jeanneret-Sozzi W, Mirimanoff R, Delaloye JF, Nobahar M, Alberto P, Bonnefoi H, Schäfer P, Krauer F, Forni M, Aapro M, Egeli R, Megevand R, Jacot-des-Combes E, Schindler A, Borisch B, Diebold S, Egli F, Willi A, Steiner R, Allemann J, Rüedi T, Leutenegger A, Dalla Torre U, Schönenberger A, Wernli M, Bargetzi M, Mingrone W, Schmid P, Bärtschi E, Beretta K.

Author information

1
Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland. olivia.pagani@ibcsg.org

Abstract

To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high.

PMID:
18953651
PMCID:
PMC3589110
DOI:
10.1007/s10549-008-0225-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center